Form 4: Heron Therapeutics EVP, CFO Ira Duarte Reports Stock Transactions
SEC Form 4
Ira Duarte, EVP and CFO of Heron Therapeutics, reports the vesting of restricted stock units and subsequent acquisition of common stock.
Summary
- On April 30, 2025, Ira Duarte, the EVP and Chief Financial Officer of Heron Therapeutics, Inc., reported a transaction involving restricted stock units.
- Specifically, 11,694 restricted stock units vested, which were then converted into 11,694 shares of common stock.
- Following this transaction, Duarte directly owns 136,149 shares of common stock and 175,416 restricted stock units.
Sentiment
Score: 5
Explanation: This is a routine disclosure of stock transactions by a company executive. It doesn't inherently indicate positive or negative sentiment.
Industry Context
Form 4 filings are standard disclosures required by the SEC when company insiders, like Ira Duarte, transact in their company's stock. These filings provide transparency to the market regarding the actions of company executives.
Stakeholder Impact
- The transaction may have a minor impact on shareholders by slightly increasing the number of outstanding shares.
Key Dates
| Date | Description |
|---|---|
| January 31, 2025 | Date of grant for the restricted stock units, which vest in 16 equal installments beginning one quarter after this date. |
| 04/30/2025 | Date of transaction: vesting of restricted stock units and acquisition of common stock. |
| 05/02/2025 | Date of signature on the Form 4 filing. |
Keywords
Heron Therapeutics, Ira Duarte, HRTX, Form 4, Stock Transaction, Restricted Stock Units, Common Stock, Beneficial Ownership, EVP, CFO
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.